Inhibikase Therapeutics announces 1-for-6 reverse stock split to regain Nasdaq compliance

Inhibikase Therapeutics, Inc.

Reverse stock split effective June 30, 2023; shares outstanding reduced from ~31.6M to ~5.3M.
Stockholder approval obtained on June 23, 2023; no fractional shares issued, fractional holders get full share.
CUSIP changed to 45719W205; trading symbol remains 'IKT'.
Proportional adjustments made to stock options and warrants exercise prices and shares.
Split intended to meet Nasdaq minimum bid price requirement.

item 3.03 item 5.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Inhibikase Therapeutics, Inc.: 1-for-6 reverse stock split via charter amendment (effective 2023-06-30).

Change: charter amendment
Effective: 2023-06-30

Exact text from the filing

On June 28, 2023, Inhibikase Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware (the “Certificate of Amendment”) to effect a 1-for-6 reverse stock split (the “Reverse Stock Split”) of the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), on June 30, 2023.

View on SEC.gov

83 governance changes filed in the last 30 days. Browse all governance changes →

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-178328

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.